Heather Han, MD

Heather Han, MD, discusses initial safety and efficacy results from the phase 2 NATASHA trial in patients with early-stage HER2-positive breast cancer.

Heather Han, MD, discusses prior research with gedatolisib that provided the rationale for the phase 3 VIKTORIA-1 trial (NCT05501886) in patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

Heather Han, MD, discusses breakthrough data from the phase 3 DESTINY-Breast04 trial.